Sandoz has completed the acquisition of Cimerli, a ranibizumab biosimilar, from Coherus BioSciences, according to a press release.
The acquisition includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, and access to proprietary commercial software, for which Sandoz paid $170 million in cash upfront.
Cimerli (ranibizumab-eqrn), which is interchangeable with Lucentis (ranibizumab, Genentech), is indicated for treating retinal diseases that may cause vision loss, and its acquisition contributes to Sandoz’s U.S. ophthalmic platform,